Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.

[1]  J. Radford,et al.  Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. , 2020, Blood.

[2]  J. Wuerthner,et al.  Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma , 2020, Blood.

[3]  K. Havenith,et al.  CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity , 2020, Journal for ImmunoTherapy of Cancer.

[4]  A. Goldberg,et al.  Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. , 2020, Leukemia research.

[5]  O. O’Connor,et al.  The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management , 2019, CA: a cancer journal for clinicians.

[6]  J. Radford,et al.  ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) , 2019, Hematological Oncology.

[7]  M. Federico,et al.  Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018 .

[8]  David C. Smith,et al.  A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma , 2018, Investigational New Drugs.

[9]  K. Savage,et al.  Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Ravandi,et al.  A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. , 2018, Blood.

[11]  J. Cerhan,et al.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.

[12]  J. Hartley,et al.  The emerging role of anti‐CD25 directed therapies as both immune modulators and targeted agents in cancer , 2017, British journal of haematology.

[13]  A. Feldman,et al.  Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms , 2017, Expert review of hematology.

[14]  Randy D Gascoyne,et al.  Non-Hodgkin lymphoma , 2016, Medicine.

[15]  M. Shipp,et al.  Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Parren,et al.  ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies , 2016, Molecular Cancer Therapeutics.

[17]  S. Ansell.  CME Information: Hodgkin Lymphoma: 2016 update on diagnosis, risk-stratification, and management , 2016 .

[18]  T. Waldmann,et al.  90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma , 2015, Proceedings of the National Academy of Sciences.

[19]  A. Nademanee,et al.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[20]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Fivenson,et al.  Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome , 2012, Leukemia & lymphoma.

[22]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  George Coukos,et al.  T-regulatory cells: key players in tumor immune escape and angiogenesis. , 2012, Cancer research.

[24]  J. Berlin,et al.  Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors , 2011, Clinical Cancer Research.

[25]  R. Hughes,et al.  Effects of Lymphoma on the Peripheral Nervous System , 1994, Journal of the Royal Society of Medicine.

[26]  B. Agnarsson,et al.  The immunophenotype of reed‐sternberg cells. A study of 50 cases of Hodgkin' disease using fixed frozen tissues , 1989, Cancer.